The Lancet reported results of a financial comparison on high dose flu vaccine verses standard flu vaccine in those 65 years of age and older. The complete study can be found below but this remark by Mark Jit, PhD, MPH Public Health England is food for thought:
Using the study’s finding, savings could reach $150 million a year if all standard-dose vaccine was replaced with its high-dose counterpart in those 65 and older.
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2815%2900272-8/fulltext
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2815%2900249-2/fulltext